Fabio G.
- Country
- Italy
- Department
- DH Oncologico
Research Overview
- Phase 3 Trial of Octreotide Subcutaneous Depot vs. Octreotide LAR or Lanreotide ATG in Unresectable/Metastatic GEP-NET Patients
- Phase II Multicenter Single-Arm Study of Durvalumab with Carboplatin or Cisplatin and Etoposide in First-Line Treatment of Extensive Stage Extrapulmonary Small Cell Carcinoma
- Phase II Multicenter Study of Metronomic Temozolomide in Clinically Frail Patients with Advanced Well-Differentiated Neuroendocrine Neoplasms
Data & Insights
Has run more than one trial at 96 of 236 partner sites.
Specializations
Colorectal Cancer Research
Leading investigations in advanced colorectal cancer treatment, with particular focus on both early-stage and metastatic disease management.
- Molecular-guided therapy approaches
- Liquid biopsy applications
- Neoadjuvant treatment strategies
Expertise in developing targeted therapies for various stages of colorectal cancer, including microsatellite stable tumors and HER2-positive disease.
Neuroendocrine Neoplasms
Specialized research in neuroendocrine tumor treatment, focusing on innovative therapeutic approaches for well-differentiated tumors.
- Low-dose therapeutic protocols
- Gastroenteropancreatic NETs
- Novel treatment combinations
Development of therapeutic strategies for frail patients with limited treatment options.
Pancreatic Cancer Studies
Active research in pancreatic ductal adenocarcinoma treatment, with emphasis on metastatic disease management.
- Advanced combination therapies
- Novel therapeutic agents
- Survival outcome improvement
Investigation of innovative treatment combinations for metastatic pancreatic cancer patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.